|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCTD9 |
Gene summary for KCTD9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCTD9 | Gene ID | 54793 |
| Gene name | potassium channel tetramerization domain containing 9 | |
| Gene Alias | BTBD27 | |
| Cytomap | 8p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q7L273 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54793 | KCTD9 | LZE4T | Human | Esophagus | ESCC | 1.52e-10 | 2.36e-01 | 0.0811 |
| 54793 | KCTD9 | LZE8T | Human | Esophagus | ESCC | 2.12e-04 | -7.66e-02 | 0.067 |
| 54793 | KCTD9 | LZE24T | Human | Esophagus | ESCC | 1.79e-06 | 8.99e-02 | 0.0596 |
| 54793 | KCTD9 | LZE6T | Human | Esophagus | ESCC | 4.16e-03 | 1.44e-02 | 0.0845 |
| 54793 | KCTD9 | P2T-E | Human | Esophagus | ESCC | 1.41e-10 | 8.94e-03 | 0.1177 |
| 54793 | KCTD9 | P4T-E | Human | Esophagus | ESCC | 1.56e-16 | 4.04e-01 | 0.1323 |
| 54793 | KCTD9 | P5T-E | Human | Esophagus | ESCC | 9.35e-12 | 7.05e-03 | 0.1327 |
| 54793 | KCTD9 | P8T-E | Human | Esophagus | ESCC | 6.29e-12 | 8.62e-02 | 0.0889 |
| 54793 | KCTD9 | P9T-E | Human | Esophagus | ESCC | 2.97e-03 | 6.92e-02 | 0.1131 |
| 54793 | KCTD9 | P10T-E | Human | Esophagus | ESCC | 1.64e-11 | 1.34e-01 | 0.116 |
| 54793 | KCTD9 | P11T-E | Human | Esophagus | ESCC | 3.97e-06 | 2.82e-01 | 0.1426 |
| 54793 | KCTD9 | P12T-E | Human | Esophagus | ESCC | 4.46e-15 | -1.85e-02 | 0.1122 |
| 54793 | KCTD9 | P15T-E | Human | Esophagus | ESCC | 7.81e-04 | -9.22e-02 | 0.1149 |
| 54793 | KCTD9 | P16T-E | Human | Esophagus | ESCC | 4.82e-14 | 1.55e-01 | 0.1153 |
| 54793 | KCTD9 | P17T-E | Human | Esophagus | ESCC | 3.74e-07 | 2.08e-01 | 0.1278 |
| 54793 | KCTD9 | P19T-E | Human | Esophagus | ESCC | 4.76e-02 | 2.98e-01 | 0.1662 |
| 54793 | KCTD9 | P20T-E | Human | Esophagus | ESCC | 3.66e-22 | 3.26e-01 | 0.1124 |
| 54793 | KCTD9 | P21T-E | Human | Esophagus | ESCC | 1.90e-14 | 2.29e-01 | 0.1617 |
| 54793 | KCTD9 | P22T-E | Human | Esophagus | ESCC | 2.70e-06 | 2.04e-02 | 0.1236 |
| 54793 | KCTD9 | P23T-E | Human | Esophagus | ESCC | 1.52e-05 | 2.83e-02 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512592 | Esophagus | ESCC | protein complex oligomerization | 130/8552 | 238/18723 | 3.29e-03 | 1.36e-02 | 130 |
| GO:0051259 | Oral cavity | OSCC | protein complex oligomerization | 121/7305 | 238/18723 | 1.29e-04 | 9.21e-04 | 121 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCTD9 | SNV | Missense_Mutation | c.734N>C | p.Leu245Ser | p.L245S | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A15R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| KCTD9 | SNV | Missense_Mutation | c.818N>T | p.Ala273Val | p.A273V | Q7L273 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | c.457N>T | p.Arg153Cys | p.R153C | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | c.304N>G | p.Thr102Ala | p.T102A | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | c.292N>T | p.Arg98Trp | p.R98W | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KCTD9 | SNV | Missense_Mutation | c.983N>T | p.Ala328Val | p.A328V | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | c.292N>T | p.Arg98Trp | p.R98W | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | novel | c.812N>G | p.Asp271Gly | p.D271G | Q7L273 | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCTD9 | SNV | Missense_Mutation | c.304N>G | p.Thr102Ala | p.T102A | Q7L273 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KCTD9 | SNV | Missense_Mutation | c.458G>A | p.Arg153His | p.R153H | Q7L273 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |